Zalicus Inc. Reports Financial Results for the Third Quarter 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the third quarter ended September 30, 2011.
“We continue to execute on our product development goals. Patient enrollment in the SYNERGY Phase 2b clinical trial of Synavive™ for rheumatoid arthritis is on track with clinical sites actively recruiting subjects across the United States, Europe and Latin America, and we are finalizing preparations to initiate clinical development of Z160, with the goal of moving quickly into Phase 2 trials with a new formulation in 2012,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “We plan to report top-line clinical results for both Synavive and our clinical-stage Ion channel programs in 2012.”
“We continue to execute on our product development goals. Patient enrollment in the SYNERGY Phase 2b clinical trial of Synavive™ for rheumatoid arthritis is on track with clinical sites actively recruiting subjects across the United States, Europe and Latin America, and we are finalizing preparations to initiate clinical development of Z160, with the goal of moving quickly into Phase 2 trials with a new formulation in 2012,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “We plan to report top-line clinical results for both Synavive and our clinical-stage Ion channel programs in 2012.”